EmboMedics Inc. has developed a bioresorbable embolic bead technology to treat uterine fibroids without causing long-term side effects. Currently in preclinical testing, EmboMedics' technology will initially be used in the treatment of uterine fibroids, although its potential for controlled and predictable drug release could lend itself to a variety of other acute and chronic indications, including liver and prostate cancer, trauma, and obesity.